Navigation Links
Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.
Date:2/27/2012

SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has hired Leomics Associates, Inc. to expand its business development activities and monetize the company's high value intellectual property estate.

"Trovagene owns a significant portfolio of molecular diagnostic intellectual property with relevance for a broad array of clinical applications. While the company will focus its internal R&D efforts on laboratory-developed tests in oncology, we are seeking development and commercialization partners for in-vitro diagnostic (IVD) opportunities, and for the development of tests in other clinical areas such as infectious disease, non-invasive prenatal diagnostics, transplant medicine, and others," stated Antonius Schuh, Ph.D.,Trovagene's Chief Executive Officer. "We are pleased to be working with Leomics Associates to execute on our business development strategy. The firm's principals have a proven track record in the industry and, amongst others, led the development of the molecular diagnostic testing business of Quest Diagnostics, the largest laboratory testing business in the United States." 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Trovagene has filed a Form 10 with the SEC. More complete current information about Trovagene is contained in the filing.

About Leomics Associates, Inc.

Leomics Associates, Inc. is a molecular diagnostics-focused consulting firm with ten years of experience, having contributed to some of the most successful molecular diagnostic projects in the industry. Leomics is led by Dr. Jorge Leon, a pioneer in the development and commercialization of molecular diagnostics, who, amongst others, helped establish the molecular diagnostic testing business at Quest Diagnostics and led its development and strategy through their critical growth years.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.

Contacts

Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com

Venanzio Ciampa
+1 (212) 217 9065
venanzio@thepromofact.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer Expands Its Hemophilia Leadership Development Program
2. AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing
3. Sanovas Expands Headquarters and Opens Manufacturing Site
4. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
5. CutisPharma Expands Product Line with New Oral Suspension Prescription Compounding Kits
6. Myoderm Expands International Capabilities
7. FDA Expands Use of Endovascular Graft to Treat Aortic Tears
8. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
9. FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
10. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
11. FDA Expands Use of HIV Drug Isentress to Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):